Difficult-to-treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results

Marc S Raab, Elena Zamagni, Salomon Manier, Paula Rodriguez-Otero, Fredrik Schjesvold, Annemiek Broijl*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

8 Downloads (Pure)


Overall outcomes for multiple myeloma have improved due to the availability of new therapies, but patients with relapsed/refractory multiple myeloma harbouring certain factors continue to pose a therapeutic challenge. These challenging features include high-risk cytogenetics, renal impairment, patient characteristics such as age and frailty, and extramedullary disease. Prior refractory status and number of prior lines add further complexity to the treatment of these patients. While newer regimens are available and have suggested efficacy in these patient populations through subgroup analyses, differences in trial definitions and cut-offs make meaningful comparisons difficult. This review aims to examine the available clinical trial data for patients with high-risk cytogenetics, renal impairment, age and frailty and extramedullary disease.

Original languageEnglish
Pages (from-to)1117-1131
Number of pages15
Issue number4
Publication statusPublished - Nov 2023

Bibliographical note

© 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.


Dive into the research topics of 'Difficult-to-treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results'. Together they form a unique fingerprint.

Cite this